Hospital

The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.

Endocrine therapy in combination with CDK4/6 inhibitors improves patients’ outcomes, but many still become treatment resistant.

Pharmacist-led interventions significantly improve antibiotic prescribing practices, optimize therapy, and improve patient outcomes.

The trial meets one of the study’s dual primary endpoints of progression-free survival, but did not meet its other primary endpoint of overall survival.

Fractyl Health also reports progress from the REMAIN-1 study evaluating weight management after discontinuing a GLP-1.

This case study underscores the critical importance of pharmacists who can provide comprehensive consideration and exploration of the appropriate treatment plan.

Challenges include therapy gaps, nonadherence, and fragmented care.

The antibody-drug conjugate shows efficacy in reducing disease progression risk and increasing progression-free survival in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer.

Kiles explores the impact of pharmacy research on health equity and education.

The cobas liat system is a closed system that aims to reduce contamination risks and enhances the reliability of results at the point of care.

Antiviral treatments for respiratory viruses such as respiratory syncytial virus (RSV) are crucial, especially with the rise of the "triple-demic."

Although the research focused on Black communities in the United States, there is also evidence linking racism and blood pressure for patients who are Asian or Hispanic.

Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Digital therapeutics (DTx), a novel evidence-based software approach, is revolutionizing health care by delivering personalized treatments. Pharmacovigilance ensures DTx safety but faces challenges such as data privacy and standardization.

Inhaling smoke can have acute effect for people with asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.

Tucatinib is an oral HER2-targeting tyrosine kinase inhibitor that was approved by the FDA in 2020.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Rates of invasive breast cancer or death were 50% lower with adjuvant trastuzumab emtansine compared with trastuzumab alone.

Pharmacists can play an important role in tobacco cessation.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

The report highlights perspective from 4 key stakeholders of patients, specialty pharmacies and providers, biopharmaceutical industry, and public and private payers.

Abelacimab (Anthos Therapeutics Inc) is a novel factor XI inhibitor being investigated for the reduction of bleeding for patients with atrial fibrillation.

USP provides health literacy standards and solutions that enhance medication safety and improve patient outcomes.

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.

The drug is being investigated as a PET diagnostic of cardiac amyloid light-chain and amyloid transthyretin-related (ATTR) amyloidosis.

This case report depicts a probable infusion reaction in a 61-year-old woman prescribed evinacumab for the treatment of familial hypercholesterolemia.